drugset / Trial / NCT05195723
Study to Assess the Safety and Pharmacokinetics of WP1122 in Healthy Volunteers
RandomizedParallel-groupTriple-blindTreatment
Summary
This study in healthy human volunteers will investigate the effects of a single dose (SAD) and multiple days of dosing (MAD) of WP1122 administered as an oral (PO) solution. Dose escalation will take place in sequential SAD cohorts, and MAD will start as soon as SAD has completed at least 3 dosing cohorts in which WP1122 is found to be safe and well-tolerated. This study in healthy volunteers will explore safety and PK, and subsequent clinical development will be in patients infected with SARS CoV-2 in the setting of continued safety and favorable risk/benefit.
Timeline
- Start
- 2022-05-11
- Primary completion
- 2022-10-24
- Completion
- 2022-10-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | WP1122 | Small molecule | — | Oral |
Indications
No indication recorded.